Vancomycin-rifampin combination therapy has enhanced efficacy against an experimental staphylococcus aureus prosthetic joint infection

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 10, 2013, Pages 5080-5086

  Niska, Jared A ^a   Shahbazian, Jonathan H ^b   Ramos, Romela Irene ^a   Francis, Kevin P ^c   Bernthal, Nicholas M ^a   Miller, Lloyd S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PERKINELMER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; EX VIVO STUDY; FEMUR; HISTOLOGY; IN VIVO STUDY; METAL IMPLANTATION; MOUSE; NONHUMAN; PERIPROSTHETIC JOINT INFECTION; PRIORITY JOURNAL; RADIOGRAPHY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS PROSTHETIC JOINT INFECTION; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; MALE; MICE; MICE, INBRED C57BL; PROSTHESIS-RELATED INFECTIONS; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 84884242692     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00702-13     Document Type: Article

References (53)

1. Del Pozo JL, Patel R. 2009. Clinical practice. Infection associated with prosthetic joints. N. Engl. J. Med. 361:787-794.
2. Parvizi J, Adeli B, Zmistowski B, Restrepo C, Greenwald AS. 2012. Management of periprosthetic joint infection: the current knowledge: AAOS exhibit selection. J. Bone Joint Surg. Am. 94:e104.
3. Arciola CR, Campoccia D, Speziale P, Montanaro L, Costerton JW. 2012. Biofilm formation in Staphylococcus implant infections.Areview of molecular mechanisms and implications for biofilm-resistant materials. Biomaterials 33:5967-5982.
4. Zimmerli W, Moser C. 2012. Pathogenesis and treatment concepts of orthopaedic biofilm infections. FEMS Immunol. Med. Microbiol. 65: 158-168.
5. Cram P, Lu X, Kates SL, Singh JA, Li Y, Wolf BR. 2012. Total knee arthroplasty volume, utilization, and outcomes among Medicare beneficiaries, 1991-2010. JAMA 308:1227-1236.
6. Wolf BR, Lu X, Li Y, Callaghan JJ, Cram P. 2012. Adverse outcomes in hip arthroplasty: long-term trends. J. Bone Joint Surg. Am. 94:e103.
7. Mortazavi SM, Schwartzenberger J, Austin MS, Purtill JJ, Parvizi J. 2010. Revision total knee arthroplasty infection: incidence and predictors. Clin. Orthop. Relat. Res. 468:2052-2059.
8. Kurtz SM, Lau E, Schmier J, Ong KL, Zhao K, Parvizi J. 2008. Infection burden for hip and knee arthroplasty in the United States. J. Arthroplasty 23:984-991.
9. Jafari SM, Coyle C, Mortazavi SM, Sharkey PF, Parvizi J. 2010. Revision hip arthroplasty: infection is the most common cause of failure. Clin. Orthop. Relat. Res. 468:2046-2051.
10. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. 2007. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J. Bone Joint Surg. Am. 89:780-785.
11. Bozic KJ, Ries MD. 2005. The impact of infection after total hip arthroplasty on hospital and surgeon resource utilization. J. Bone Joint Surg. Am. 87:1746-1751.
12. Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J. 2012. Economic burden of periprosthetic joint infection in the United States. J. Arthroplasty 27:61-65.
13. Parvizi J, Pawasarat IM, Azzam KA, Joshi A, Hansen EN, Bozic KJ. 2010. Periprosthetic joint infection: the economic impact of methicillinresistant infections. J. Arthroplasty 25:103-107.
14. Jackson WO, Schmalzried TP. 2000. Limited role of direct exchange arthroplasty in the treatment of infected total hip replacements. Clin. Orthop. Relat. Res. 101-105.
15. Jamsen E, Stogiannidis I, Malmivaara A, Pajamaki J, Puolakka T, Konttinen YT. 2009. Outcome of prosthesis exchange for infected knee arthroplasty: the effect of treatment approach. Acta Orthop. 80:67-77.
16. Klouche S, Leonard P, Zeller V, Lhotellier L, Graff W, Leclerc P, Mamoudy P, Sariali E. 2012. Infected total hip arthroplasty revision: oneor two-stage procedure? Orthop. Traumatol. Surg. Res. 98:144-150.
17. Singer J, Merz A, Frommelt L, Fink B. 2012. High rate of infection control with one-stage revision of septic knee prostheses excluding MRSA and MRSE. Clin. Orthop. Relat. Res. 470:1461-1471.
18. Koyonos L, Zmistowski B, Della Valle CJ, Parvizi J. 2011. Infection control rate of irrigation and debridement for periprosthetic joint infection. Clin. Orthop. Relat. Res. 469:3043-3048.
19. Marculescu CE, Berbari EF, Hanssen AD, Steckelberg JM, Harmsen SW, Mandrekar JN, Osmon DR. 2006. Outcome of prosthetic joint infections treated with debridement and retention of components. Clin. Infect. Dis. 42:471-478.
20. Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, Rao N, Hanssen A, Wilson WR. 2013. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin. Infect. Dis. 56:e1- e25.
21. Bernthal NM, Stavrakis AI, Billi F, Cho JS, Kremen TJ, Simon SI, Cheung AL, Finerman GA, Lieberman JR, Adams JS, Miller LS. 2010. A mouse model of post-arthroplasty Staphylococcus aureus joint infection to evaluate in vivo the efficacy of antimicrobial implant coatings. PLoS One 5:e12580. doi:10.1371/journal.pone.0012580.
22. Niska JA, Meganck JA, Pribaz JR, Shahbazian JH, Lim E, Zhang N, Rice BW, Akin A, Ramos RI, Bernthal NM, Francis KP, Miller LS. 2012. Monitoring bacterial burden, inflammation and bone damage longitudinally using optical and muCT imaging in an orthopaedic implant infection in mice. PLoS One 7:e47397. doi:10.1371/journal.pone.0047397.
23. Niska JA, Shahbazian JH, Ramos RI, Pribaz JR, Billi F, Francis KP, Miller LS. 2012. Daptomycin and tigecycline have broader effective dose ranges than vancomycin as prophylaxis against a Staphylococcus aureus surgical implant infection in mice. Antimicrob. Agents Chemother. 56: 2590-2597.
24. Pribaz JR, Bernthal NM, Billi F, Cho JS, Ramos RI, Guo Y, Cheung AL, Francis KP, Miller LS. 2012. Mouse model of chronic post-arthroplasty infection: noninvasive in vivo bioluminescence imaging to monitor bacterial burden for long-term study. J. Orthop. Res. 30:335-340.
25. Lora-Tamayo J, Murillo O, Iribarren JA, Soriano A, Sanchez-Somolinos M, Baraia-Etxaburu JM, Rico A, Palomino J, Rodriguez-Pardo D, Horcajada JP, Benito N, Bahamonde A, Granados A, Del Toro MD, Cobo J, Riera M, Ramos A, Jover-Saenz A, Ariza J. 2013. A large multicenter study of methicillin-susceptible and methicillin-resistant Staphylococcus aureus prosthetic joint infections managed with implant retention. Clin. Infect. Dis. 56:182-194.
26. Senneville E, Joulie D, Legout L, Valette M, Dezeque H, Beltrand E, Rosele B, d'Escrivan T, Loiez C, Caillaux M, Yazdanpanah Y, Maynou C, Migaud H. 2011. Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to Staphylococcus aureus. Clin. Infect. Dis. 53:334-340.
27. Widmer AF, Gaechter A, Ochsner PE, Zimmerli W. 1992. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin. Infect. Dis. 14:1251-1253.
28. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. 1998. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 279:1537-1541.
29. Brand AM, de Kwaadsteniet M, Dicks LM. 2010. The ability of nisin F to control Staphylococcus aureus infection in the peritoneal cavity, as studied in mice. Lett. Appl. Microbiol. 51:645-649.
30. Hegde SS, Skinner R, Lewis SR, Krause KM, Blais J, Benton BM. 2010. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia. J. Antimicrob. Chemother. 65:725-728.
31. Crandon JL, Kuti JL, Nicolau DP. 2010. Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillinresistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model. Antimicrob. Agents Chemother. 54:5115- 5119.
32. Reyes N, Skinner R, Benton BM, Krause KM, Shelton J, Obedencio GP, Hegde SS. 2006. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58:462-465.
33. Sakoulas G, Eliopoulos GM, Alder J, Eliopoulos CT. 2003. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1714-1718.
34. Landersdorfer CB, Bulitta JB, Kinzig M, Holzgrabe U, Sorgel F. 2009. Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin. Pharmacokinet. 48:89-124.
35. Sakoulas G, Moellering RC, Jr., Eliopoulos GM. 2006. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin. Infect. Dis. 42(Suppl. 1):S40 -S50.
36. Williams I, Paul F, Lloyd D, Jepras R, Critchley I, Newman M, Warrack J, Giokarini T, Hayes AJ, Randerson PF, Venables WA. 1999. Flow cytometry and other techniques show that Staphylococcus aureus undergoes significant physiological changes in the early stages of surfaceattached culture. Microbiology 145:1325-1333.
37. Reipert A, Ehlert K, Kast T, Bierbaum G. 2003. Morphological and genetic differences in two isogenic Staphylococcus aureus strains with decreased susceptibilities to vancomycin. Antimicrob. Agents Chemother. 47:568-576.
38. Calvori C, Frontali L, Leoni L, Tecce G. 1965. Effect of rifamycin on protein synthesis. Nature 207:417-418.
39. Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, Darst SA. 2001. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104:901-912.
40. John AK, Baldoni D, Haschke M, Rentsch K, Schaerli P, Zimmerli W, Trampuz A. 2009. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob. Agents Chemother. 53:2719-2724.
41. Parra-Ruiz J, Vidaillac C, Rose WE, Rybak MJ. 2010. Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. Antimicrob. Agents Chemother. 54:4329- 4334.
42. Raad I, Hanna H, Jiang Y, Dvorak T, Reitzel R, Chaiban G, Sherertz R, Hachem R. 2007. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob. Agents Chemother. 51:1656-1660.
43. Saginur R, Stdenis M, Ferris W, Aaron SD, Chan F, Lee C, Ramotar K. 2006. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob. Agents Chemother. 50: 55-61.
44. Saleh-Mghir A, Muller-Serieys C, Dinh A, Massias L, Cremieux AC. 2011. Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 55:4589-4593.
45. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak J, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52:e18-e55.
46. Calleja C, Pascussi JM, Mani JC, Maurel P, Vilarem MJ. 1998. The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor. Nat. Med. 4:92-96.
47. Bi W, Zhu L, Wang C, Liang Y, Liu J, Shi Q, Tao E. 2011. Rifampicin inhibits microglial inflammation and improves neuron survival against inflammation. Brain Res. 1395:12-20.
48. Mlambo G, Sigola LB. 2003. Rifampicin and dexamethasone have similar effects on macrophage phagocytosis of zymosan, but differ in their effects on nitrite and TNF-alpha production. Int. Immunopharmacol. 3:513- 522.
49. Brinkmann KC, Talati AJ, Akbari RE, Meals EA, English BK. 2005. Group B streptococci exposed to rifampin or clindamycin (versus ampicillin or cefotaxime) stimulate reduced production of inflammatory mediators by murine macrophages. Pediatr. Res. 57:419-423.
50. An N, Song Y, Zhang X, Ci X, Li H, Cao Y, Zhang M, Cui J, Deng X. 2008. Pretreatment of mice with rifampicin prolongs survival of endotoxic shock by modulating the levels of inflammatory cytokines. Immunopharmacol. Immunotoxicol. 30:437-446.
51. Baker-Lepain JC, Nakamura MC, Lane NE. 2011. Effects of inflammation on bone: an update. Curr. Opin. Rheumatol. 23:389-395.
52. Pascussi JM, Robert A, Nguyen M, Walrant-Debray O, Garabedian M, Martin P, Pineau T, Saric J, Navarro F, Maurel P, Vilarem MJ. 2005. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J. Clin. Invest. 115:177-186.
53. Wang Z, Lin YS, Dickmann LJ, Poulton EJ, Eaton DL, Lampe JW, Shen DD, Davis CL, Shuhart MC, Thummel KE. 2013. Enhancement of hepatic 4-hydroxylation of 25-hydroxyvitamin D3 through CYP3A4 induction in vitro and in vivo: implications for drug-induced osteomalacia. J. Bone Miner. Res. 28:1101-1116.